The inhibition of CDK7 can therefore block multiple RTK signals and prevent the reactivation of multiple kinase pathways in HER2-targeted remedy-resistant breast cancer but is not capable of silencing all the nodes of downstream intracellular signaling. This evidence concerns the gene ERBB2 and breast carcinoma.